TARS - Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids
- Tarsus Pharmaceuticals ( NASDAQ: TARS ) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of TP-03 to treat Demodex blepharitis.
- Demodex blepharitis is inflammation of the eyelids caused by a type of mite called Demodex. The disease does not have any FDA-approved therapy, the company said in a Sept. 7 press release.
- Tarsus noted that the NDA was backed by data from two trials (Saturn-1 and Saturn-2) collectively involving more than 800 patients in which TP-03 (lotilaner ophthalmic solution, 0.25%) met all goals and was well-tolerated.
For further details see:
Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids